Description

R715 is a selective bradykinin B1 receptor antagonist. R715 significantly attenuates the hyperalgesic effect developed in Streptozotocin(HY-13753)-diabetic mice[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)—-C57H81N13O12—-[1]Gabra BH, et al. Beneficial effect of chronic treatment with the selective bradykinin B1 receptor antagonists, R-715 and R-954, in attenuating streptozotocin-diabetic thermal hyperalgesia in mice. Peptides. 2003;24(8):1131-1139.–185052-09-9–1140.33–99.45–O=C(N1[C@@H](CCC1)C(NCC(N[C@H](C(N[C@@H](CO)C(N[C@@H](C(N[C@H](C(O)=O)[C@@H](C)CC)=O)CC2=CC3=C(C=CC=C3)C=C2)=O)=O)CC4=CC=CC=C4)=O)=O)[C@H]5N(CCC5)C([C@H](CCCNC(N)=N)NC([C@@H](NC(C)=O)CCCCN)=O)=O–Others–DMSO : 100 mg/mL (ultrasonic)–Bradykinin Receptor—-GPCR/G Protein–Peptides